ILIsmail D. Legason

Ismail D. Legason

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ismail D. Legason has a total of 138 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Analysis of Epstein–Barr Virus and Tumor‐Derived Circulating Plasma DNA in Children and Young Adults With Classical Hodgkin Lymphoma in East Africa

    by Clara Chamba, Heavenlight Christopher, Emmanuel Josephat, Julius Sseruyange, Alisen Ayitewala, Helene Dreau, Adam Burns, Isaac Otim, Priscus Mapendo, Leah Mnango, et al.

    Background: Pediatric Hodgkin lymphoma in sub‐Saharan Africa is frequently associated with Epstein–Barr virus (EBV), providing a unique opportunity to investigate the molecular characteristics and clinical significance of EBV‐associated disease in an understudied population. Procedures: We conducted an observational cohort study of 50 children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) in Tanzania and Uganda. Plasma cell‐free DNA collected at diagnosis was analyzed for circulating tumor DNA (ctDNA), EBV‐derived biomarkers, and somatic mutations. Associations between clinical, molecular, and survival outcomes were assessed using correlation analyses and Cox proportional hazards models. Results: The median age was 12 years and 62% of participants were male. Most patients presented with advanced‐stage disease. ctDNA was detected in 60% of patients with a low mutational burden, while EBV DNA was detected in 92% of cases. Male patients exhibited higher EBV‐derived markers and fewer TNFAIP3 and B2M mutations. At a median follow‐up of 17.2 months, overall survival was 84% and event‐free survival was 50%; male sex and elevated lactate dehydrogenase independently predicted inferior event‐free survival. Conclusions: These findings reveal a low mutational burden and sex‐associated molecular and clinical differences in EBV‐positive cHL.

  • Open Access

    Liquid biopsy for the diagnosis of EBV-positive Burkitt’s lymphoma in endemic areas

    by Clara Chamba, Heavenlight Christopher, Emmanuel Josephat, Julius Sseruyange, Alisen Ayitewala, Kieran Howard, Helene Dreau, Adam Burns, Ismail Legason, Isaac Otim, et al.

    Burkitt’s lymphoma (BL) is common in sub-Saharan Africa, yet diagnosis is often delayed due to limited pathology capacity. Here we evaluated blood-based liquid biopsies from 377 children and young adults with clinically suspected lymphoma at four hospitals in Tanzania and Uganda, assessing diagnostic accuracy and turnaround time (TAT). After extensive pathology capacity building, a gold-standard diagnosis was established using tissue morphology, a limited validated immunohistochemistry panel and independent dual histopathologist review. Using clinical features and circulating tumor DNA markers ( MYC mutations, MYC –immunoglobulin translocations and Epstein–Barr virus fragmentomics), we trained six penalized logistic regression models with tenfold crossvalidation ( n = 212). The best-performing model was externally validated in a prospective real-world cohort ( n = 56). Diagnostic accuracy, yield and TAT were compared head to head between liquid biopsy and the gold standard in 58 participants. The comprehensive model achieved the highest performance (area under the curve (AUC) 0.95, 95% confidence interval (95% CI) 0.901–0.981, sensitivity 0.86, specificity 0.95), confirmed by external validation (AUC 0.98, 95% CI 0.942–1.000). Liquid biopsy was the only diagnostic result available at the multidisciplinary review in 42% of participants and reduced median diagnostic TAT from 46.8 d to 6.5 d ( P = 4.42 × 10 −10 ). These findings demonstrate that liquid biopsy enables fast, highly accurate molecular diagnosis of EBV + BL and may substantially reduce treatment delays in resource-limited settings.


  • Open Access

    Pooled prevalence and factors associated with insecticide-treated net use among pregnant women in malaria high-burden countries in sub-Saharan Africa: a multilevel mixed-effects analysis

    by Edson Mwebesa, Benson Musinguzi, Ismail D. Legason, Robert Opoke, Bosco B. Agaba, Rornald Muhumuza Kananura, Ann Mwangi

    Introduction: Malaria remains a significant public health challenge among pregnant women in sub-Saharan Africa (SSA). Proper use of insecticide-treated nets (ITNs) is a key intervention for malaria; however, their utilisation remains low and suboptimal in high-burden countries. Investigation of correlates of use of ITNs among pregnant women in only high-burden malaria countries SSA are dearth. This study aimed to identify the pooled prevalence and factors associated with ITNs use among pregnant women in seven malaria high-burden countries in SSA. Methods: Secondary analysis of recent (2017–2021) Malaria Indicator Survey (MIS) data from seven malaria high-burden countries in SSA was utilised. Women aged 15–49 years, who were pregnant during the survey, were included in this study, resulting in a pooled sample size of 4950 women. Pooled prevalence of ITN use was obtained through the use of proportions, with a 95% confidence interval (CI). A multilevel mixed-effect logistic regression model was run to obtain factors associated with ITNs use among pregnant women at 5% level of significance. Data analysis was done in Stata v17.0 and R 4.5.0. Findings: The pooled prevalence of ITNs use among these countries was 63.8 [95% CI 61.8, 65.9], low in Ghana (49.2%) and high in Niger (90.5%). Having a primary level of education [aOR = 1.36, 95% CI 1.21, 1.53] compared to those with no formal education, having given birth to one to two children [aOR = 1.24, 95% CI 1.06, 1.44] compared to those with no births yet were associated with higher odds of ITN use. 14% of the total variation in ITN use was attributable to differences between countries [intra-cluster correlation (ICC) = 0.14, 95% CI 0.06, 0.20] and 32% of the variation in ITN use within countries is attributed to differences between regions [ICC = 0.32, 95% CI 0.21, 0.46]. Conclusions: The prevalence of ITN use was suboptimal, and socio-demographic and household factors are associated with ITN use among pregnant women, with substantial in-country variation underscoring the role of regional context in ITN utilization. These findings suggest that beyond individual and household determinants, local and regional contexts play a critical role in shaping ITN usage patterns. Interventions should, therefore, be tailored not only to socio-demographic profiles but also to regional and local disparities in access, awareness, and implementation effectiveness.


  • Open Access

    Evidence of latent-lytic replication in EBV-positive Burkitt lymphoma from whole genome and transcriptome sequencing

    by Ismail Legason, Adam Burns, Dimitrios Vavoulis, Silvia Halim, Helene Dréau, Daisy Jennings, Hadijah Nabalende, Isaac Otim, Martin Ogwang, Julius Sseruyange, et al.

    Epstein–Barr virus (EBV) is a ubiquitous human herpesvirus linked to multiple malignancies, but its role in disease remains uncertain. We analysed 410 EBV genomes, including 64 newly sequenced isolates from plasma of East African children with and without Burkitt lymphoma (BL), integrating whole-genome and transcriptomic data. Population genomic analyses revealed marked regional structure with strain-level diversity shaped by both recombination and mutation, particularly within latency and immune-evasion genes (EBNA-1, LMP-1, BCRF1, BNLF2a), reflecting selective pressure from host immunity and tumour microenvironment. We identified a BL-associated mutational signature (SBS_EBV3) enriched for T > C and C > T substitutions in G-rich contexts, with limited similarity to known COSMIC signatures (closest match SBS54, cosine similarity 0.74). Transcriptomic profiling demonstrated a mixed latent–lytic expression programme in BL, potentially promoting recombination and mutagenesis. These findings define new features of EBV evolution in BL and highlight opportunities for diagnostics and vaccines targeting both latent and lytic antigens.

  • Open Access

    Rituximab for children with EBV-positive Burkitt lymphoma in East Africa

    by William Frank Mawalla, Caroline Achola, Hadijah Nabalende, Isaac Otim, Ismail D. Legason, Martin D. Ogwang, Pamella M. Aol, Godlove Sandi, Hadija Mwamtemi, Salama Mahawi, et al.

    The addition of rituximab to the chemotherapy backbone was shown to significantly improve outcomes of children with aggressive high-grade lymphomas in high-income countries. However, data on its safety and efficacy in children with Epstein-Barr virus (EBV)–positive Burkitt lymphoma (BL) are limited. We conducted a prospective nonrandomized observational study in East African patients aged ≤25 years with confirmed BL. Patients received either the International Network for Cancer Treatment and Research (INCTR)–based standard chemotherapy (cyclophosphamide, vincristine, and methotrexate [COM]) or rituximab plus standard chemotherapy (R-COM). The primary end point was safety. The secondary outcomes were event-free and overall survival and cost-effectiveness of incorporating rituximab. Primary analyses were conducted in the intention-to-treat population. The median follow-up was 23 months. Safety analyses included 72 patients: 32 in the COM group and 40 in the R-COM group. Grade ≥3 adverse events occurred in 18% of R-COM patients and 16% of COM patients. With respect to treatment outcomes at 12 months, 5 events were observed in the R-COM group and 14 in the COM group. The 12-month event-free survival was 67% with R-COM and 43% with COM (hazard ratio [HR], 0.49; 95% confidence interval [CI], 0.24-0.98; P = .045). There were 8 deaths in the R-COM group, whereas 16 patients died in the COM group (HR, 0.32; 95% CI, 0.14-0.75; P = .009). R-COM was particularly effective in advanced-stage disease. The addition of rituximab to the INCTR-based protocol (COM) for EBV-positive BL has been observed to be safe and feasible in experienced centers in East Africa and saves lives.


  • Open Access

    Targeted Next-Generation Sequencing of Cell-Free DNA to Detect MYC -Immunoglobulin Translocation and Epstein-Barr Virus DNA in Plasma of Burkitt Lymphoma Patients in East Africa

    by Clara Chamba, Daisy Jennings, Rehema Shungu, Heavenlight Christopher, Emmanuel Josephat, Kieran Howard, Helene Dreau, Adam Burns, William Mawalla, Priscus Mapendo, et al.

    PURPOSE: Epstein-Barr virus (EBV)–positive Burkitt lymphoma (BL) affects children in sub-Saharan Africa, but diagnosis via tissue biopsy is challenging. We explored a liquid biopsy approach using targeted next-generation sequencing to detect the MYC -immunoglobulin ( MYC -Ig) translocation and EBV DNA, assessing its potential for minimally invasive BL diagnosis. MATERIALS AND METHODS: The panel included targets for the characteristic MYC -Ig translocation, mutations in intron 1 of MYC , mutations in exon 2 of MYC , and three EBV genes: EBV-encoded RNA (EBER)1, EBER2, and EBV nuclear antigen 2. It was first tested in a small derivation cohort of four precharacterized BL-derived cell lines with known translocation status and eight precharacterized plasma samples with known EBV DNA status by quantitative polymerase chain reaction (qPCR). These different data modalities were combined to assess the accuracy of this approach in the diagnosis of BL in 20 patient plasma samples in Tanzania and Uganda. RESULTS: The next-generation sequencing panel detected three of four MYC -Ig translocations in the BL-derived cell lines. EBV viral load by targeted sequencing correlated strongly with qPCR results (Spearman's rho = 0.94) in precharacterized plasma samples. Using the patient plasma samples, mutations in MYC intron 1 were associated with the presence of a MYC translocation with 25 or more mutations being predictive of a translocation with AUC, sensitivity, and specificity of 1. Overall, liquid biopsy parameters associated with a diagnosis of BL ( P < .05) included cell-free DNA concentration, circulating tumor DNA concentration, MYC intron 1 mutations, MYC -Ig translocation, and autosome entropy. Integrating these parameters into a diagnostic model demonstrated excellent performance with an AUC of 0.95, sensitivity of 0.9, and specificity of 1. CONCLUSION: This analysis demonstrates the potential of liquid biopsy to improve BL diagnosis in settings with limited pathology resources. Validation of our approach in a larger data set is needed.


  • Open Access

    Human leukocyte antigen-DQA1*04:01 and rs2040406 variants are associated with elevated risk of childhood Burkitt lymphoma

    by Zhiwei Liu, Yang Luo, Samuel Kirimunda, Murielle Verboom, Olusegun O. Onabajo, Mateus H. Gouveia, Martin D. Ogwang, Patrick Kerchan, Steven J. Reynolds, Constance N. Tenge, et al.

    Burkitt lymphoma (BL) is responsible for many childhood cancers in sub-Saharan Africa, where it is linked to recurrent or chronic infection by Epstein-Barr virus or Plasmodium falciparum. However, whether human leukocyte antigen (HLA) polymorphisms, which regulate immune response, are associated with BL has not been well investigated, which limits our understanding of BL etiology. Here we investigate this association among 4,645 children aged 0-15 years, 800 with BL, enrolled in Uganda, Tanzania, Kenya, and Malawi. HLA alleles are imputed with accuracy >90% for HLA class I and 85-89% for class II alleles. BL risk is elevated with HLA-DQA1*04:01 (adjusted odds ratio [OR] = 1.61, 95% confidence interval [CI] = 1.32-1.97, P = 3.71 × 10−6), with rs2040406(G) in HLA-DQA1 region (OR = 1.43, 95% CI = 1.26-1.63, P = 4.62 × 10−8), and with amino acid Gln at position 53 versus other variants in HLA-DQA1 (OR = 1.36, P = 2.06 × 10−6). The associations with HLA-DQA1*04:01 (OR = 1.29, P = 0.03) and rs2040406(G) (OR = 1.68, P = 0.019) persist in mutually adjusted models. The higher risk rs2040406(G) variant for BL is associated with decreased HLA-DQB1 expression in eQTLs in EBV transformed lymphocytes. Our results support the role of HLA variation in the etiology of BL and suggest that a promising area of research might be understanding the link between HLA variation and EBV control.


  • Open Access

    Mosaic chromosomal alterations in peripheral blood leukocytes of children in sub-Saharan Africa

    by Weiyin Zhou, Anja Fischer, Martin D. Ogwang, Wen Luo, Patrick Kerchan, Steven J. Reynolds, Constance N. Tenge, Pamela A. Were, Robert T. Kuremu, Walter N. Wekesa, et al.

    In high-income countries, mosaic chromosomal alterations in peripheral blood leukocytes are associated with an elevated risk of adverse health outcomes, including hematologic malignancies. We investigate mosaic chromosomal alterations in sub-Saharan Africa among 931 children with Burkitt lymphoma, an aggressive lymphoma commonly characterized by immunoglobulin-MYC chromosomal rearrangements, 3822 Burkitt lymphoma-free children, and 674 cancer-free men from Ghana. We find autosomal and X chromosome mosaic chromosomal alterations in 3.4% and 1.7% of Burkitt lymphoma-free children, and 8.4% and 3.7% of children with Burkitt lymphoma (P-values = 5.7×10−11 and 3.74×10−2, respectively). Autosomal mosaic chromosomal alterations are detected in 14.0% of Ghanaian men and increase with age. Mosaic chromosomal alterations in Burkitt lymphoma cases include gains on chromosomes 1q and 8, the latter spanning MYC, while mosaic chromosomal alterations in Burkitt lymphoma-free children include copy-neutral loss of heterozygosity on chromosomes 10, 14, and 16. Our results highlight mosaic chromosomal alterations in sub-Saharan African populations as a promising area of research.


  • Open Access

    High prevalence of malaria in pregnancy among women attending antenatal care at a large referral hospital in northwestern Uganda: A cross-sectional study

    by Caleb Mangusho, Edson Mwebesa, Jonathan Izudi, Mary Aleni, Ratib Dricile, Richard M. Ayiasi, Ismail D. Legason

    Background: Malaria in pregnancy contributes to substantial morbidity and mortality among women in Uganda. However, there is limited information on the prevalence and factors associated with malaria in pregnancy among women in Arua district, northwestern Uganda. We, therefore, assessed the prevalence and factors associated with malaria in pregnancy among women attending routine antenatal care (ANC) clinics at Arua regional referral hospital in north-western Uganda. Methods: We conducted an analytic cross-sectional study between October and December 2021. We used a paper-based structured questionnaire to collect data on maternal socio-demographic and obstetric factors and malaria preventive measures. Malaria in pregnancy was defined as a positive rapid malarial antigen test during ANC visits. We performed a modified Poisson regression analysis with robust standard errors to determine factors independently associated with malaria in pregnancy, reported as adjusted prevalence ratios (aPR) and 95% confidence intervals (CI). Results: We studied 238 pregnant women with a mean age of 25.32±5.79 years that attended the ANC clinic, all without symptomatic malaria. Of the participants, 173 (72.7%) were in their second or third trimester, 117 (49.2%) were first or second-time pregnant women, and 212 (89.1%) reported sleeping under insecticide-treated bednets (ITNs) every day. The prevalence of malaria in pregnancy was 26.1% (62/238) by rapid diagnostic testing (RDT), with the independently associated factors being daily use of insecticide-treated bednets (aPR 0.41, 95% CI 0.28, 0.62), first ANC visit after 12 weeks of gestation (aPR1.78, 95% CI 1.05, 3.03), and being in the second or third trimester (aPR 0.45, 95% CI 0.26, 0.76). Conclusion: The prevalence of malaria in pregnancy among women attending ANC in this setting is high. We recommend the provision of insecticide-treated bednets to all pregnant women and early ANC attendance to enable access to malaria preventive therapy and related interventions.